Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 2, 2018

Primary Completion Date

October 10, 2018

Study Completion Date

February 6, 2019

Conditions

Uterine FibroidsEndometriosis

Interventions

DRUG

Vilaprisan (BAY1002670)

Single oral dose (1 x 2 mg immediate-release, film-coated tablet)

Trial Locations (2)

Orlando Clinical Research Center, Orlando

Clinical Pharmacology of Miami, Inc., Miami